Amylyx Pharmaceuticals Announces $472M Public Stock Offering

What Happened
Amylyx Pharmaceuticals, Inc. filed an 8-K on August 20, 2026, disclosing an underwriting agreement entered August 19, 2026, to sell 14,090,000 shares of its common stock at $35.50 per share (the “Offering”). The company granted the underwriters a 30‑day option to buy up to 2,113,500 additional shares. The Offering is expected to close on August 21, 2026, subject to customary closing conditions.

Key Details

• Offering size: 14,090,000 firm shares at $35.50 per share.
• Option: Underwriters may buy up to 2,113,500 additional shares within 30 days.
• Estimated net proceeds to Amylyx: approximately $471.7 million; about $542.5 million if option exercised in full.
• Use of proceeds: fund potential U.S. commercial launch of avexitide (if approved), expand manufacturing capacity, R&D, working capital and general corporate purposes.
• Underwriters: Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC. Prospectus supplement filed August 19, 2026.

Why It Matters
This offering will materially increase Amylyx’s cash resources to support a potential commercial launch of avexitide and related manufacturing scale-up. For investors, the deal dilutes existing shareholders because the company is issuing new shares; it also reduces funding risk for near-term commercialization and development plans if the full proceeds are received. The underwriters’ option could further increase dilution and cash raised if exercised.